Experimental antibody takes on brain cancer in tiny trial
NCT ID NCT06922604
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This early-phase trial tests a drug called glofitamab, given after a pre-treatment with obinutuzumab, in 20 adults with central nervous system lymphoma. The goal is to check safety and side effects. Glofitamab is a bispecific antibody that helps the immune system attack cancer cells. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Glofitamab (a bispecific antibody) with obinutuzumab pre-treatment
- What this could lead to
- If it works, this could point toward a new treatment option for central nervous system lymphoma, a hard-to-treat cancer.
- What could go wrong
- This is a very early phase 1b trial with only 20 participants, focused on safety. It may not show enough benefit or could have serious side effects like cytokine release syndrome or nerve toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immune booster outsmart brain lymphoma?
- Can a daily pill keep brain lymphoma at bay after remission?
- Can a Brain-Penetrating drug tackle recurrent CNS lymphoma?
- New antibody combo aims to treat brain lymphoma
- Could a cancer drug shrink recurrent brain tumors?
- New cocktail aims to shrink brain tumors